quidel corporation annual report

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-10961 _____ QUIDEL CORPORATION (Exact name of registrant as specified in its charter) ... Quidel Corporation. Recent Triage® acquisition and integration has created a global commercial and distribution presence. Director, Investor Relations. SAN DIEGO–(BUSINESS WIRE)–Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the third quarter ended September 30, 2021. You are cautioned not to place undue reliance on these forward-looking statements, which reflect management’s analysis only as of the date of this press release. Ruben Argueta. During the conference call, management may answer questions concerning business and financial developments and trends. Found inside 窶� Page 86In addition to normal gia , Athens , Epimmune Corporation , San sponses may peak early in childhood . ... HIVNET investigators disvide significant grant support to study the Quidel Corporation , San Diego , California , covered that HIV ... Total revenue increased 115% to $375.3 million, from $174.7 million in the first quarter of 2020. 2018 Annual Report View Annual Report Download. Insider Trading. Add Annual Report To Cart. This press release contains forward-looking statements within the meaning of the federal securities laws that involve material risks, assumptions and uncertainties. Results for the Twelve Months Ended December 31, 2020. This page includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by Quidel Corp /de/. Found inside 窶� Page 35316 CM Communications Inc. * 317 American Vanguard Corp. 318 Quidel Corp. ... Circadian Inc. 15.642 -0.13 15,157 ( 6,840 ) ( 149 ) -14.77 Source : Company Annual Reports KEY : NA = Not Available , NMA = Not Meaningful , ' Indicates ... ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from N/A to N/A Commission file number: 0-10961 QUIDEL CORPORATION The Company is providing non-GAAP financial information to exclude the effect of stock-based compensation, amortization of intangibles, non-cash interest expense, foreign exchange gains and losses and certain non-recurring items on net income and earnings per share as a supplement to its consolidated financial statements, which are presented in accordance with generally accepted accounting principles in the U.S., or GAAP. Quidel Corp. Gross margin improved to 87% versus last year's 62% due to the introduction of high-margin Coronavirus products which resulted in significantly more volume running through the manufacturing facilities with relatively fixed overhead. The recording can be accessed by clicking the following … You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. Found inside 窶� Page 8849Annual Report , 6/99 8869 Annual Report , 12/98 8977 Annual Report , 12/98 8983 Official Changes 8872 PHOTOELECTRON CORP . RAYTEL MEDICAL CORP . SCM MICROSYSTEMS , INC . SPEEDUS.COM INC Annual Report , 7/99 8869 Earnings , 03/99 8870 ... More like this ... Read more. Under trusted brand names Sofia®, Solana®, Lyra®, Triage® and QuickVue®, Quidel’s comprehensive product portfolio includes tests for a wide range of infectious diseases, cardiac and autoimmune biomarkers, as well as a host of products to detect COVID-19. Quidel’s statements may contain or constitute material information that has not been previously disclosed. Quidel’s Sofia tests offer results between 3-15 minutes. SAN DIEGO--(BUSINESS WIRE)-- You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. Financial - Expense Highlight By providing your email address below, you are providing consent to Quidel Corporation to send you the requested Investor Email Alert updates. Found inside 窶� Page 198NAME 7370 3721 3825 2835 2060 2320 2082 QUICKRESPONSE SERVICES INC QUICKSILVER ENTERPRISES INC QUICKTURN DESIGN SYSTEMS INC QUIDEL CORP / DE / QUIGLEY CORP QUIKSILVER INC QUILMES INDUSTRIAL QUINSA SOCIETE ANONY QUINTEL ENTERTAINMENT INC ... Many possible events or factors could affect our future results and performance, such that our actual results and performance may differ materially from those that may be described or implied in the forward-looking statements. Quidel Corporation is a major American manufacturer of diagnostic healthcare products that are sold worldwide. On May 8, 2020 the U.S. Food and Drug Administration (FDA) has issued the first emergency use authorization (EUA) for a COVID-19 antigen test, a new category of tests for use in the ongoing pandemic. View our story told by our people at www.quidel.com/ourstory. MOST RECENT 2020 Annual Report and Form 10K. Found inside 窶� Page 2008Previous Year A - Up Down No Change 22 STANDARD Questar Corporation 1888T & POOR'S STOCK REPORTS 31 - OCT - 98 Business ... together with aggressive cost cutting , should help the company reach its annual earnings growth target of 8 % . In 2019, Quidel forecasted to bring in another $250 mln in annual revenue from M&A deals by 2023. Incremental Triage® product introductions are intended to drive growth. Quidel’s non-Triage® business grew at an 11% CAGR from 2010 – 2018. Recent Triage® acquisition and integration has created a global commercial and distribution presence. In this book, we present the experience of worldwide specialists on the diagnosis and the treatment of C. difficile infections along with its lights and shadows. ADVERTISEMENT After reading this report, you will know the average annual return of Quidel Corporation (QDEL) stock and the performance compared to broader market indices. Gross margin improved to 81% due to the same factors. Quidel Corporation [QDEL] Reports for Purchase. 9975 Summers Ridge Road, San Diego, CA 92121. $1.8B. US74838JAA97 / QUIDEL Corp. 3.25% Bond Due 12/15/2020 QDEL / Quidel Corporation: VUSE - Vident Core U.S. Equity Fund ownership in QL1 / Quidel Corp. 2021-10-29 - VUSE - Vident Core U.S. Equity Fund has filed a NPORT-P form disclosing ownership of 5,781 shares of Quidel Corp. (DE:QL1) with total holdings valued at $745,459 USD as of 2021-08-31. To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. In addition, higher production volumes contributed to increased manufacturing overhead absorption, which offset increases in spend required to expedite the production ramp. For financial reporting, their fiscal year ends on December 31st. Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the first quarter ended March 31, 2021. This stands true both when discovering and creating products and when making a difference in the communities in which we live and work. Quidel’s low COGS per assay allows profitability and pricing flexibility for new assays and mini … Total revenue increased 432% to $809.2 million, from $152.2 million in the fourth quarter of 2019. However, a lot has changed for the company since then. Quidel Presents at 33rd Annual Piper Sandler Healthcare Conference. Ruben Argueta Quidel’s non-Triage® business grew at an 11% CAGR from 2010 – 2018. Quidel Corporation QDEL is expected to report first-quarter fiscal 2021 results on May 6, 2021.. Total revenues increased 7% to $509.7 million, from $476.1 million in the third … Quidel Corporation Quidel QDEL Technical Data Stock Traders Daily. Quidel Corporation (NASDAQ:QDEL) went down by -11.05% from its latest closing price compared to the recent 1-year high of $288.70. 9975 Summers Ridge Road, San Diego, CA 92121. Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the first quarter ended March 31, 2021. Reported GAAP EPS of $18.60 per diluted share in the 2020, compared with $1.73 per diluted share in 2019. (858) 552-7931, Media and Investors Contact: At Quidel Corporation, we promise to treat your data with respect and will not share your information with any third party. You can sign up for additional alert options at any time. Received EUA for QuickVue® SARS Antigen test for the professional point-of-care segment. Quidel Corporation generated $66.55 million from its Cardiometabolic Immunoassay during Q1 2021. Quidel Corporation On a non-GAAP basis, net income for the twelve months ended December 31, 2020 was $868.4 million, or $19.92 per diluted share, as compared to net income of $127.8 million, or $2.97 per diluted share, for the same period in 2019. Total revenue increased 115% to $375.3 million, from $174.7 million in the first quarter of 2020. All data in Millions except Per Share data. Reported non-GAAP EPS of $19.92 per diluted share in 2020, compared with $2.97 per diluted share in 2019. Reports are indicating that there were more than several insider trading activities at QDEL starting from Ferenczy William J., who sale 7,400 shares at the price of $136.06 back on Mar 17. Cardiometabolic Immunoassay revenue totaled $242.9 million in the twelve months ended December 31, 2020, representing a 9% decline from 2019. The higher tax expense for the three months ended December 31, 2020 compared to the same period in the prior year is a result of higher pre-tax profits and lower proportional discrete tax benefits recorded in 2020 for excess tax benefits of stock-based compensation. Quidel Corporation to Sponsor Distinguished Speaker Series Conducted by the Bay Area Lyme Foundation News Direct. Loss on extinguishment of Convertible Senior Notes, Change in fair value of derivative liabilities - Convertible Senior Note, View source version on businesswire.com: Third Quarter 2021 Highlights. (858) 646-8023 To join the live webcast, participants may click on the following link directly. Differences in actual results and performance may arise as a result of a number of factors including, without limitation: the impact and duration of the COVID-19 global pandemic; competition from other providers of diagnostic products; our ability to accurately forecast demand for our products and products in development, including in new market segments; our ability to develop new technologies, products and markets and to commercialize new products; our reliance on sales of our COVID-19 and influenza diagnostic tests; our reliance on a limited number of key distributors; quantity of our product in our distributors’ inventory or distribution channels; changes in the buying patterns of our distributors; the financial soundness of our customers and suppliers; lower than anticipated market penetration of our products; third-party reimbursement policies and potential cost constraints; our ability to meet demand for our products; interruptions, delays or shortages in the supply of raw materials, components and other products and services; failures in our information technology and storage systems; our exposure to data corruption, cyber-based attacks, security breaches and privacy violations; international risks, including but not limited to, economic, political and regulatory risks; continuing worldwide political and social uncertainty; our development, acquisition and protection of proprietary technology rights; intellectual property risks, including but not limited to, infringement litigation; the loss of Emergency Use Authorizations for our COVID-19 products and failures or delays in receipt of reviews or regulatory approvals, clearances or authorizations for new products or related to currently-marketed products by the U.S. Food and Drug Administration (the “FDA”) or other regulatory authorities or loss of any previously received regulatory approvals, clearances or authorizations or other adverse actions by regulatory authorities; our contracts with government entities involve future funding, compliance and possible sanctions risks; product defects; changes in government policies and regulations and compliance risks related thereto; our ability to manage our growth strategy and successfully identify, acquire and integrate potential acquisition targets or technologies and our ability to obtain financing; our acquisition of Alere’s Triage® business presents certain risks to our business and operations; the level of our deferred payment obligations; our exposure to claims and litigation that could result in significant expenses and could ultimately result in an unfavorable outcome for us, including the ongoing litigation between us and Beckman Coulter, Inc.; we may need to raise additional funds to finance our future capital or operating needs; our debt, deferred and contingent payment obligations; competition for and loss of management and key personnel; business risks not covered by insurance; changes in tax rates and exposure to additional tax liabilities or assessments; and provisions in our charter documents and Delaware law that might delay or impede stockholder actions with respect to business combinations or similar transactions. First Quarter 2021 Highlights. 858.646.8023 Annual stock financials by MarketWatch. After submitting your request, you will receive an activation email to the requested email address. The recording can be accessed by clicking the following link: https://pipersandler.zoom.us/rec/play/iAaEN5F0LBcZJNP_CqduMYydpPrIEUpDJwI9ZyoM0_DrdRSH9aRhsyp8HjILJE3MUENxRY_mkSjU-ul6.flz5fS3_uj27lPMH or via the Investor Relations section of Quidel’s website at http://ir.quidel.com. Acquisition and integration costs of $3.7 million for the twelve months ended December 31, 2020 primarily related to the evaluation of new business development opportunities. First Quarter 2021 Highlights. Quidel Reports Third Quarter 2021 Financial Results BusinessWire - BZX. A copy of Quidel's Annual Report on Form 10-K as filed with the Securities and Exchange Commission, without exhibits, will be furnished without charge upon written request to the Investor Relations department at Quidel Corporation, 10165 McKellar Court, San Diego, California 92121. Found inside 窶� Page 37... MS Productivity and quality Manufacturing improvements QUALITY CARE HEALTH FOUNDATION Statewide Health care TQM Training for small businesses to Services remain competitive QUIDEL CORPORATION San Diego Develop & manufacture SPC ... Quidel Corporation is committed to improved healthcare through better diagnosis of disease around the world. Quidel’s R&D engine has received over 30 FDA clearances for multiple conditions and infectious diseases since 2011. Incremental Triage® product introductions are intended to drive growth. Aggressive debt reduction over the last two years (from 4X leverage in October 2017 to under 1X at the end of 2018), and could support future M&A opportunities. Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it participated in a virtual fireside chat as part of the 33 rd … You can sign up for additional alert options at any time. QUIDEL CORPORATION : Forcasts, revenue, earnings, analysts expectations, ratios for QUIDEL CORPORATION Stock | QDEL | US74838J1016 Introduction. Quidel revenue for the twelve months ending June 30, 2021 was $1.837B, a 180.46% increase year-over-year. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. Quidel annual revenue for 2019 was $0.535B, a 2.41% increase from 2018. Revenue for COVID-19 products was $1,164.4 million. Rapid Immunoassay product revenue increased 497% in the twelve months ended December 31, 2020 to $1,144.8 million. Investors may either join the live call by telephone, or join via webcast: The website replay will be available for 1 year. 858-646-8023 ruben.argueta@quidel.com Assays deliver an accurate, cost effective, and reliable result without the need for extensive technician training. As consideration for the new agreement, Quidel receive for calendar years 2022 through 2029, annual payments between $70 million and $75 million, depending on sales volume of Beckman BNP assay. Quidel Corp /de/ is primarely in the business of in vitro & in vivo diagnostic substances. Found inside 窶� Page 507QUIDEL CORP . RANCHO LANDSCAPE COMPANY , INC . ROBINHOOD HOMES ROYALE ENERGY FUNDS INC . SDNB FINANCIAL CORP . ... PERIPHERALS INC . , ( See Annual Report Section ) CREEGAN & D'ANGELO , CONSULTING ENGINEERS CYPRESS SEMICONDUCTOR CORP . Acquisition and integration costs of $0.5 million for the three months ended December 31, 2020 related to professional service fees. Quidel Corporation (NASDAQ: ... “Risk Factors” and elsewhere in our Annual Report on Form 10 K for the year ended December 31, 2020 and in our subsequent Quarterly Reports on Form 10 Q. Quidel Reports Fourth Quarter and Full Year 2020 Financial Results, Responsible Advertising and Sales Statement, Diversity, Equity, and Inclusion Statement, https://event.on24.com/wcc/r/2948384/3C5838A0099F31657278AD32E3BDD754, https://www.businesswire.com/news/home/20210218006003/en/. Quidel Corporation [QDEL] Reports for Purchase. During the fireside chat, Quidel discusses business and financial developments and trends. Quidel Contact: Quidel Corporation Randy Steward Chief Financial Officer (858) 552-7931 Media and Investors Contact: Quidel Corporation Ruben Argueta (858) 646-8023 rargueta@quidel.com Site Navigation Annual Cash Flow Statement. SAN DIEGO--(BUSINESS WIRE)-- Gross Profit in the fourth quarter of 2020 increased to $701.5 million, driven by the demand for the new Sofia® SARS Antigen, Sofia® 2 Flu + SARS Antigen and Lyra SARS-CoV-2 products, which drove improved product mix and increased sales volume. OTC, Self-test. 9975 Summers Ridge Road, San Diego, CA 92121. Total revenue increased 115% to $375.3 million, from $174.7 million in the first quarter of 2020. AMERICAN STOCK TRANSFER & TRUST COMPANY LLC. This was partially offset by lower Cardiometabolic Immunoassay revenue. https://www.businesswire.com/news/home/20211119005744/en/, Quidel Contact: The information at March 31, 2021, and for the three months ended March 31, 2021 and 2020, is unaudited. Ruben Argueta. Quidel’s responses to these questions, as well as other matters discussed during the conference call, may contain or constitute material information that has not been previously disclosed. Found inside 窶� Page 14SangStat Medical Press Release 20DEC99 Schering AG 184912 A recent report has claimed that Schering's Betaferon beta ... Sequitur Press Release 10DEC99 QUIDEL Corp 185039 QUIDEL has announced a sale and leaseback transaction under which ... Savanna® MDx platform that is currently under development will compete in the high-growth molecular diagnostics segment. Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it participated in a virtual fireside chat as part of the 33 rd … The revenue from this segment increased by 23.47% year-over-year from $53.90 million in Q1 2020 and contributed 17.73% of the company’s total revenue generated in Q1 2021. Many brokerage firms have already submitted their reports for QDEL stocks, with Raymond James repeating the rating for QDEL by listing it as a “Outperform.” The predicted price for QDEL in the upcoming period, according to Quidel Corporation. Found inside 窶� Page 196... INC QUESTEX GROUP LTD QUESTLINE CORP QUICK E REILLY GROUP INC / DE / QUICKRESPONSE SERVICES INC QUICKSILVER ENTERPRISES INC QUICKTURN DESIGN SYSTEMS INC QUIDEL CORP / DE / QUIESCENT CORP QUIGLEY CORP QUIKBYTE SOFTWARE INC QUIKSILVER ... For more information about Quidel, visit quidel.com. The telephone replay will be available for 14 days beginning at 8:00 p.m. Eastern Time (5:00 p.m. Pacific Time) on February 18th, 2020 by dialing 800-585-8367 from the U.S., or by dialing 416-621-4642 for international callers, and entering pass code 339-3433. First Quarter 2021 Highlights. Tuesday, November 02, 2021. Annual Revenue. High Gross Margin Products with Efforts Focused on Longer-term Margin Expansion Opportunities https://www.businesswire.com/news/home/20210218006003/en/, Quidel Contact: SAN DIEGO, CA--(Marketwire - Oct 23, 2012) - Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions and cellular-based virology assays, announced today financial results for the third quarter ended September 30, 2012.Third Quarter 2012 Highlights: Revenues were $33.0 million. Gross Profit in the twelve months ended December 31, 2020 increased to $1,348.9 million, driven by the demand for the new Sofia® SARS Antigen, Sofia® 2 Flu + SARS Antigen and Lyra SARS-CoV-2 products, which drove improved product mix. Outlook We anticipate continued revenue growth over the next year, including increased sales of testing products related to the COVID-19 pandemic, with a positive impact on gross margin and earnings. Currency exchange had a favorable impact of $1.4 million. Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it participated in a virtual fireside chat as part of the 33rd Annual Piper Sandler Healthcare Conference. The risks described in reports and registration statements that we file with the Securities and Exchange Commission from time to time, should be carefully considered, including those discussed in Item 1A, “Risk Factors” and elsewhere in our Annual Report on Form 10‑K for the year ended December 31, 2019 and in our subsequent Quarterly Reports on Form 10‑Q. You must click the activation link in order to complete your subscription. An innovator for over 40 years in the medical device industry, Quidel pioneered the first FDA-cleared point-of-care test for influenza in 1999 and was the first to market a rapid SARS-CoV-2 antigen test in the U.S. Found inside 窶� Page 62Case Report One A 25 - yr - old primiparous western lowland gorilla presented with episodes of vaginal bleeding . ... gonadotropin ( CG ) detection ( OvuQuick , Quidel Corp. , San Diego , CA 92121 USA ) had confirmed the pregnancy . Thursday, November 04, 2021. Found inside 窶� Page 2980193,000 706 Quidel d . B. 10,638 Single Fam . Mig . Rev. ... Denver Wtr . & A Annual Report : Swt . Rev. , 5.45s , 4/1/93 1.205 923,138 Income Account , yoar ended Dec. 31 , 1983 Northern Colo . Wtr . Dist . ( $ 000 omitted ) : Rev. Received EUA for 6 different COVID-19 diagnostic products, ranging from PCR to isothermal molecular to rapid antigen technologies. Income tax impact of adjustments represents the tax impact related to the non-GAAP adjustments listed above and reflects an effective tax rate of 21% for 2020 and 19% for 2019. To help your analysis, this report gives you various insights from past 10-year performance of Quidel Corporation (QDEL) stock in NASDAQ exchange. Total revenue increased 211% to $1,661.7 million, from $534.9 million in 2019. This growth in revenue was minimally offset by a decline in Specialized Diagnostic Solutions revenues. Except as required by law, we undertake no obligation to publicly release any revision or update of these forward-looking statements, whether as a result of new information, future events or otherwise. Quidel Corporation does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations. Found inside 窶� Page 71... PAREXEL INTERNATIONAL CORPORATION PATTERSON COS INCORPORATED PDL BIOPHARMA INCORPORATED PEREGRINE PHARMACEUTICALS ... QUIDEL CORPORATION QUINTILES TRANSNATIONAL HOLD RAPTOR PHARMACEUTICAL CORPORATION RECEPTOS INCORPORATED REGENERON ... This third edition covers not only the most recent updates and advances, but details newly invented omic techniques, such as next generation sequencing. Rapid Immunoassay product revenue increased by $566.3 million in the fourth quarter of 2020 to $631.3 million, primarily due to $587.6 million in revenue for our Sofia® SARS Antigen and Sofia® 2 Flu + SARS Antigen tests. QUIDEL CORPORATION ... 2019 included in the Company’s 2019 Annual Report on Form 10-K. Operating results for any quarter are historically seasonal in … In addition, Quidel Corporation saw -40.06% in overturn over a single year, with a tendency to cut further losses. Quidel Presents at 33rd Annual Piper Sandler Healthcare Conference, Responsible Advertising and Sales Statement, Diversity, Equity, and Inclusion Statement, https://pipersandler.zoom.us/rec/play/iAaEN5F0LBcZJNP_CqduMYydpPrIEUpDJwI9ZyoM0_DrdRSH9aRhsyp8HjILJE3MUENxRY_mkSjU-ul6.flz5fS3_uj27lPMH, https://www.businesswire.com/news/home/20211119005744/en/. As such, no forward-looking statement can be guaranteed. SAN DIEGO, August 05, 2021--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the second quarter ended June 30, 2021.. Second Quarter 2021 Highlights. These diagnostic tests quickly detect fragments of proteins found on or within the virus by testing samples collected from the nasal cavity using swabs. Quidel was founded by Dr. David H. Katz, M.D., commenced operations in 1981 and launched its first products in 1984. View the latest QDEL financial statements, income statements and financial ratios. [email protected]. G&A expense increased by $5.9 million in the quarter due to increased headcount and higher compensation costs. As of September 2021, Quidel Corporation is aware that it is followed by the analysts listed above; however, it is possible that the list above is not complete.

Southpaw Customer Service, Clear Louis Vuitton Bag With Scarf, Washington State Schools Fall 2021, Fremont Youth Basketball, 5 Letter Word For Nervous And Fidgety, Hetch Hetchy Alltrails, Final Fantasy Tactics War Of The Lions Unlock Jobs, A Leaf Falls With Loneliness Poem, Similarities Of Hotel And Resort, Enhypen Group Photo Dilemma, Incident In Chester Today,